In this ambispective cohort study of patients referred to an outpatient Infectious Diseases Clinic for chronic HCV, we found significant differences in patient demographics, drug interactions, and time to treat between HCV monoinfected and HIV/HCV coinfected patients. This study provides a broad, yet concise overview of the differences in caring for patients with and without HIV/HCV coinfection.

The objective of this study was to better define the association of hepatitis C-positive donors with heart transplant volumes, wait-list duration, and mortality at 1 year. Findings suggest that infection is well-tolerated and curable in heart transplant recipients with donor-derived hepatitis C, and 1-year survival is equivalent to that in recipients of hepatitis C-negative donors.

This study highlighted baseline factors associated with HCV treatment failure in 1,253 patients at four United States institutions. Most likely predictors of treatment failure in our dataset were older age, presence of hepatocellular carcinoma, and private versus public insurance, which appeared in 89%, 84%, and 80% of bootstrap models, respectively.

Rates of persistent viremia (PV), defined as a detectable hepatitis c (HCV) viral load after 4 weeks of direct-acting antiviral (DAA) therapy, were low (5.7%) in a real-world cohort of 983 patients. High sustained virologic response (SVR) rates were achieved both in patients with PV (92.9%) and those with rapid virologic response (RVR) (96.5%), without significant differences.

This case series describes the safety and effectiveness outcomes of patietns requiring HCV DAA tablet manipulation. This data along with a comprehensive review of other reports of DAA manipulation demonstrate the safety and efficacy of tablet manipulation.

This report discusses reasons anticancer therapies may need to be initiated on admission, challenges of doing so, perspectives and experiences from 3 unique HSSPs on addressing these challenges, and finally, best practice recommendations in managing high cost oral anticancer therapies for admitted patients.

The purpose of this article is to describe medication alternatives available for use in patients with certain bleeding disorders during the intranasal desmopressin recall. Intranasal desmopressin plays a key role in treatment of these patients and the recall is expected to impact availability until mid to late 2023. We hope the details of the article can help other institutions select the best treatment alternative for their patients during this time.

This study found that integrating a pharmacist into clinic significantly shortened time from treatment decision to shipment for LDD drugs, partially overcoming access barriers. Additionally, access to LDDs was still slower than non-LDDs as they cannot be fully integrated into clinic workflow. The integrated specialty pharmacy program adds value to patient access and outperforms LDDs, challenging the value of LDD networks beyond medical economics.

This is a phase IV single-arm study prospectively evaluating the safety and efficacy of apixaban for primary prevention of VTE in patients with MM. The study found that during the 6 month evaluation no patients experienced major hemorrhagic events, MI, stroke, or death. Three patients did have non-major events that were medically managed and one patient discontinued therapy because of an allergic reaction to apixaban.

Ivosidenib is the first approved oral, targeted, small molecule inhibitor of the isocitrate dehydrogenase 1 (IDH1) mutation seen in acute myeloid leukemia. This review article discusses the clinical trials and dose escalation studies conducted to secure the U.S. Food and Drug Administration approval.